Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 16/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 12/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587914 | 0.93 | MAPKAPK2 (1.00) | MAPKAPK2MAPK9AURKAKDRADORA2A | |
| SCHEMBL3581632 | 0.92 | MAPKAPK2 (0.91) | MAPKAPK2MAPK9AURKAKDRADORA2A | |
| SCHEMBL3569274 | 0.91 | MAPKAPK2 (1.00) | MAPKAPK2MAPK9AURKAKDR | |
| SCHEMBL3575206 | 0.83 | MAPKAPK2 (1.00) | MAPKAPK2MAPK9AURKAKDR | |
| SCHEMBL3581009 | 0.83 | MAPKAPK2 (0.75) | MAPKAPK2MAPK9 | |
| SCHEMBL3580312 | 0.82 | MAPKAPK2 (1.00) | MAPKAPK2MAPK9 | |
| SCHEMBL3579073 | 0.81 | MAPKAPK2 (0.80) | MAPKAPK2MAPK9 | |
| SCHEMBL3582763 | 0.75 | MAPKAPK2 (1.00) | MAPKAPK2MAPK9 | |
| SCHEMBL3575684 | 0.74 | MAPKAPK2 (0.59) | MAPKAPK2MAPK9AURKAKDRMET | |
| SCHEMBL3575688 | 0.74 | MAPKAPK2 (0.59) | MAPKAPK2MAPK9AURKAKDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069360-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | claimed |
| US-20100069360-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069360-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069360-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| WO-2008025512-A1 | PYRROLO ISOQUINOLINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069360-A1 | ORGANIC COMPOUNDS | SLCO1B3, CYP3A7, SLCO1B1 | MAPKAPK2 4563/4885MAPK9 2834/4885AURKA 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.